Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Low-income Californians who use GLP-1s for weight loss lost their coverage at the start of the new year, with officials advising diet and exercise instead.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...

California and other states say the drugs are too costly, even as the Trump administration announces plans to lower prices.

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug candidate, teeing the drugmaker up to target people taking Novo Nordisk’s ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. When HCA Healthcare, one ...

Lymphedema after head and neck cancer is considerably more common than previously assumed and can persist long after cancer treatment has finished. Researchers at Lund University in Sweden have ...

Headache wasn’t reported as a side effect in Zepbound’s studies. But, it may be a symptom of some of Zepbound’s side effects. More common side effects of Zepbound are digestive side effects, such as ...

Retatrutide shows highest weight loss to date in trial Lilly says trial departures due to perceived excessive weight loss Retatrutide shows elevated skin-related side effects Dec 11 (Reuters) - Eli ...